Rheumatology (Oxford). 2017 May 1;56(5):679-688. doi: 10.1093/rheumatology/kew293.
PMID:27498351
Secondary gout.
GARDNER FH, NATHAN DG.
Med Clin North Am. 1961 Sep;45:1273-82. doi: 10.1016/s0025-7125(16)33834-2.
PMID:13703606
Diagnosis, treatment, and prevention of gout.
Hainer BL, Matheson E, Wilkes RT.
Am Fam Physician. 2014 Dec 15;90(12):831-6.
PMID:25591183
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
PMID:16339094
Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.
Sun J, Wang Y, Cheng Y, Guo D, Hu J, Liu D, Gao Z, Li C, Lu Y, Kong X, Liu Y, Jiang Z, Yi B, Zhang H, Xu B, Yu S, Kokan R, Ishikawa K, Kawakatsu M, Zhang Z.
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.
McCormick N, Yokose C, Lu N, Wexler DJ, Aviña-Zubieta JA, De Vera MA, Chigurupati S, Tan K, Chen C, McCoy R, Curhan GC, Choi HK.
BMJ. 2024 Oct 30;387:e080035. doi: 10.1136/bmj-2024-080035.